The Role of the E3 Ligase Cbl-B in Murine Dendritic Cells

Stephanie Wallner1,2, Christina Lutz-Nicoladoni1,2, Christoph H. Tripp3, Günther Gastl1,2, Gottfried Baier4, Josef M. Penninger5, Patrizia Stoitzner3, Dominik Wolf1,6*

1 Laboratory of Tumor Immunology, Tyrolean Cancer Research Institute, Innsbruck, Austria, 2 Internal Medicine V, Haematology and Oncology, Innsbruck, Austria, 3 Department of Dermatology and Venerology, Medical University Innsbruck, Innsbruck, Austria, 4 Department for Medical Genetics, Molecular and Clinical Pharmacology, Medical University Innsbruck, Innsbruck, Austria, 5 IMBA, Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria, 6 Department of Hematology and Oncology, University Hospital Bonn, Bonn, Germany

Abstract

Dendritic cells (DCs) are potent antigen-presenting cells with a promising potential in cancer immunotherapy. Cbl proteins are E3 ubiquitin ligases and have been implicated in regulating the functional activity of various immune cells. As an example, c-Cbl negatively affects DC activation. We here describe that another member of the Cbl-protein family (i.e. Cbl-b) is highly expressed in murine bone-marrow-derived DCs (BMDCs). Differentiation of cblb−/− bone marrow mononuclear cells into classical BMDCs is unaltered, except enhanced induction of DEC-205 (CD205) expression. When tested in mixed-lymphocyte reaction (MLR), cblb−/− BMDCs exhibit increased allo-stimulatory capacity in vitro. BMDCs were next in vitro stimulated by various toll-like receptor (TLR)-agonists (LPS, Poly(I:C), Cpg) and exposed to FITC-labeled dextran. Upon TLR-stimulation, cblb−/− BMDCs produce higher levels of proinflammatory cytokines (IL-1α, IL-6 and TNF-α) and exhibit a slightly higher level of FITC-dextran uptake. To further characterize the functional significance of cblb−/− BMDCs we tested them in antigen-specific T cell responses against ovalbumin (OVA) protein and peptides, activating either CD8+ or CD4+ T cells. OT-II transgenic T cells. However, cblb−/− BMDCs are equally effective in inducing antigen-specific T cell responses when compared to wildtype BMDCs both in vitro and in vivo. The migratory capacity into lymph nodes during inflammation was similarly not affected by the absence of Cbl-b. In line with these observations, cblb−/− -peptide-pulsed BMDCs are equally effective vaccines against OVA-expressing B16 tumors in vivo when compared to wildtype BMDCs. We conclude that in contrast to c-Cbl, Cbl-b plays only a limited role in the induction of Ag-specific T cell responses by murine BMDCs in vitro and in vivo.

Introduction

DCs are a unique class of leukocytes whose primary function is to capture antigens and process them to activate or tolerize T cells [1]. Thus, the high efficacy of DCs in initiating primary T cell responses inspired tumor immunologists to evaluate the therapeutic potential of DCs as cellular vaccine to induce antigen-specific immune responses targeting cancer cell associated antigens [2]. However, despite huge efforts to establish DC vaccination as a treatment for cancer patients, therapeutic success is limited so far. Nevertheless, a randomized trial in hormone-refractory prostate cancer led to the first FDA approval of a DC-based vaccine after observation of an improved overall survival rate of DC-treated patients, whereas numerous other studies (i.e. in melanoma etc.) did not yield positive clinical results [3,4]. Thus, at least in the current application schedules DC vaccines do not sufficiently help cancer patients by inducing significant clinical responses, in spite of consistently measurable T cell responses and a virtual lack of therapy-related side-effects [5,6]. Therefore improvement of DC vaccines is a clear unmet medical need.

Casitas b-lineage lymphoma proto-oncogene b (Cbl-b) is a member of a highly evolutionary conserved family of Cbl proteins, which in mammals consists of three Cbl genes: Cbl (also termed c-Cbl, Cbl2, RNF55), Cbl-b (also termed RNF56) and Cbl-c/Cbl-3 (also termed, Cbl-SL, RNF57) [7,8]. Cbl proteins interact with target proteins via their protein-protein interaction domains, allowing regulation of multiple signaling pathways in immune cells [8].

The E3 ubiquitin ligase c-Cbl, known for its roles in regulating lymphocyte signaling has now been identified to be a modulator of DC activation as well [9]. In cbl−/− DCs, Toll-like receptor (TLR)-induced expression of proinflammatory cytokines such as IL-12p70, IL-6, IL-1α and IL-1β was significantly enhanced. This correlated with a greater potency of DC-based vaccines against established tumors when cbl−/− DCs were used [9]. A recent study indicates that the E3 ubiquitin ligase Cbl-b plays a critical role in the regulation of TLR-triggered inflammatory response via degradation of MyD88, which is a central component of TLR-signaling [10–13]. Additionally, the interaction between programmed cell death ligand 1 (PD-L1) on DCs and programmed cell death 1 (PD-1) on CD8+ T cells contributes to ligand-induced TCR down-modulation, which occurs via Cbl-b up-regulation in CD8+ T cells. PD-L1/PD-1 interference enhances CD8+ T cell anti-tumor activities by interfering with Cbl-b up-regulation [14,15]. Further studies demonstrated that blocking of PD-1...
causes reduced Cbl-b expression and blocking of PD-L1/PD-1 blockade is also showing very promising results in the clinic [16,17]. So far, the role of Cbl-b in DC biology has not been addressed. Substantial evidence already supports an important role for Cbl-b in various cells of the immune system. More precisely, Cbl-b has been described as a critical gatekeeper of anergy avoidance pathway in T and NKT cells [18–23]. This knowledge has recently been used to improve the efficacy of adoptive T cell therapy by using cblb−/− T cells as cellular therapy, as this renders T cells resistant to inhibitory cues of the tumor microenvironment allowing improved cancer regression rates [24–27]. According to this idea, we recently published that the adoptive transfer of cblb−/− CD8+ T cells in combination with a DC vaccination in immune-competent mice significantly delays tumor growth in various mouse tumor models [28]. Moreover, at least in defined cellular systems such as osteoclastogenesis or thymocyte development Cbl-b and c-Cbl have redundant functions [29,30]. These data support the idea, that targeting the Cbl-b pathway may be a promising strategy to enhance anti-tumor efficacy by potentially not only interfering with tumor genesis or thymocyte development Cbl-b and c-Cbl have delays tumor growth in various mouse tumor models [28]. Furthermore, at least in defined cellular systems such as osteoclastogenesis or thymocyte development Cbl-b and c-Cbl have redundant functions [29,30]. These data support the idea, that targeting the Cbl-b pathway may be a promising strategy to enhance anti-tumor efficacy by potentially not only interfering with tumor cell but also by modulating DC biology. Based on these ideas we systematically tested impact of cblb-deficiency on the biological behaviour of murine DCs to finally evaluate whether anti-tumor responses could further be improved by using cblb−/− DCs instead of wildtype DCs for vaccination.

**Materials and Methods**

**Mice**

Cblb mutant mice were crossed into a C57BL/6 background and genotyped by PCR. Littermate control groups were used and mice of inbred strains C57BL/6, BALB/c, C57BL/6-OT-I and C57BL/6-OT-II were purchased from Charles River Laboratories (Germany) and used at the age of 7–12 weeks, sex and age matched. T cells from OT-I and OT-II mice express a transgenic Vz2β1.5/2 T cell receptor (TCR) specific for the OVA peptides presented on H2-Kb (amino acids 257 to 264; SIINFEKL) or on I-Ab (amino acids 323 to 339; ISQAVHAA-HAEINEAGR), respectively. Mice were maintained under specific-pathogen-free conditions. This study was carried out in strict accordance with protocols approved by the Institutional Animal Care and Use Committee of the Medical University Innsbruck (Permit Numbers: 66011/116-II/10b/2008, 66011/146-II/3b/2012). All surgery was performed under anesthesia, and all efforts were made to minimize suffering.

**Generation of BMDCs**

BMDCs were generated following a modified protocol described earlier [31]. Briefly, bone marrow was collected by flushing the tibia and femora of cblb−/− and wildtype mice, cultured in RPMI supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 0.05 mM β-mercaptoethanol and 200 U/ml granulocyte-macrophage colony-stimulating factor (GM-CSF), obtained from supernatant of X38-Ag8 plasmacytoma cells (kind gift of A. Lanzavecchia, Bellinzona, CH). For in vitro studies immature (not exposed to LPS) and mature DGs induced by incubating day seven non-adherent BMDCs with 100 ng/ml LPS (Sigma Aldrich) over night were used. For in vivo vaccination studies we used semi-mature BMDCs exposed for 4 hours to LPS.

**Flow Cytometric Analysis of Cell Surface Marker**

Cell suspensions from spleen and lymph nodes were prepared by teasing the organs into small fragments with scissors followed by digestion with 0.25 mg/mL collagenase P (Roche Diagnostics) and 120 µg/mL DNase I (Roche Diagnostics) for 30 minutes at 37°C. After digestion tissue was pressed through cell strainers (70 µm, BD Falcon), essentially as described recently for spleen cell suspensions [32]. Flow cytometry analyses were performed to analyze BMDCs from wildtype and cblb−/− mice. Briefly, 1×10⁶ cells in 100 µL of flow buffer (ice-cold PBS plus 1% FCS) were stained with fluorescently-labeled cell surface-specific primary antibodies for 30 min at 4°C. Cells were washed twice with flow buffer. All flow cytometry data were acquired using a multi-colour flow cytometer (FACSCalibur or FACSaria, BD Biosciences) equipped with the CellQuest Pro™ or FACSDiv™ software (BD Biosciences). Staining was performed with following, directly labeled, monoclonal antibodies: MHC II/1-A/1-E-PE-Cy7 (clone M5/114.15.2) antibody was purchased from eBioscience, CD11c-PerCP (clone N418), CD205/DEC-205-APC (clone NLDC-145), CD83-FTTC (clone Michel-19), MHC II/1-A/1-E-PerCP (clone M5/114.15.2), CD80-PerCP/Cy5.5 (clone 16-10A1), CD40-PE (clone 3/23), CD14-PE/Cy7 (clone Sa14-2), CCR7-APC (clone 4B12) from Biologend and Macrophage Mannose receptor/ CD206-Alexa Fluor 647 (clone MR3D3) from Serotec. Data analysis was performed using FlowJo™ software (Tree Star).

**Isolation of CD4 and CD8 T cells**

CD8+ and CD4+OVA-specific T cells were isolated from spleen and lymph node suspensions obtained from OT-I and OT-II transgenic mice by using magnetic bead separation (CD4+ T cell isolation kit; CD8+ T cell isolation kit; Miltenyi Biotec). Briefly, non-CD4+ or CD8+ T cells were depleted using a biotinylated antibody cocktail. The purity of both populations was assessed by flow cytometric analysis and routinely yielded a purity of 85–95%. The T cells from BALB/c mice for MLR were prepared by passing spleen suspensions through cell strainer and T cells were isolated with magnetic beads (Pan T cell isolation kit; Miltenyi Biotec).

**In vitro Antigen-specific T cell Proliferation**

CD8+ and CD4+OVA-specific T cells were isolated from OT-I and OT-II transgenic mice, respectively. Wildtype and cblb−/− BMDCs were matured with 100 ng/ml LPS and primed with SIINFEKL peptide (amino acids 257 to 264; SIINFEKL; Promimmune) or I-Ab peptide (amino acids 323 to 339; ISQAV-HAAHAEINEAGR; AnaSpec Inc.) overnight. BMDCs were applied in graded doses in triplicates to 2×10⁵ transgenic CD8+ or CD4+ T cells in 96-well round-bottomed culture plates for 48 hours. Proliferation of T cells was measured by uptake of 1 µCi ³H-Thymidine (Hartmann Analytik Braunschweig, Germany) pulsed for the last 16–18 hours of incubation by using a β-scintillator (MicroBeta Tri-Lax, Perkin Elmer).

**In vivo Antigen-specific T cell Proliferation Assay**

CD8+OVA-specific T cells were enriched from suspensions of lymph node and spleens of OT-I transgenic mice by negative selection (Miltenyi Biotec). CD8+ T cells were labeled at 2×10⁶ cells/ml with 2 µM carboxy-fluorescein diacetate succinimidyl ester (CFSE; Invitrogen-Molecular Probes) for 10 min at 37°C. The reaction was quenched with an equal volume of FCS and cells were washed three times with PBS/0.1% BSA. C57BL/6 recipient mice were injected intravenously with 5×10⁶ CFSE-labeled transgenic CD8+ T cells. 24 hours thereafter we subcutaneously injected 5×10⁶ BMDCs which had been matured with 100 ng/ml LPS and pulsed in vitro with or without 10 µM SIINFEKL peptide (Promimmune) at 37°C overnight. Cell suspensions were prepared from draining (inguinal) and non-draining lymph node 72 hours
later by pressing the lymph nodes through cell strainers with the plunger of a syringe. Groups of 3 mice per treatment were used routinely. Proliferation of antigen-specific CD8+ CFSE+ T cells was detected by the decrease of CFSE fluorescence intensity as described earlier [33].

**Cross-presentation-Assay**

CD8+ and CD4+ OVA-specific T cells were isolated from OT-I and OT-II transgenic mice respectively. Wildtype and cblb−/− BMDCs were matured with 100 ng/ml LPS and loaded with 1 mg/ml OVA-protein (Sigma Aldrich) overnight. BMDCs were applied in graded doses in triplicates to 2×105 freshly prepared OT-I transgenic CD8+ and OT-II transgenic CD4+ T cells in 96-well round-bottomed culture plates for 48 hours. Proliferation of T cells was measured by uptake of 1 μCi 3H-Thymidine (Hartmann Analytik) pulsed for the last 16–18 hours of incubation.

**Mixed Lymphocyte Reaction**

For MLR experiments, suspensions of responder T cells were cultured with mature allogeneic stimulator BMDCs. BMDCs of C57BL/6 mice were matured with 100 ng/ml LPS for 24 hours. T cells were purified from the spleens of Balb/c mice by negative magnetic bead isolation (Pan T cell isolation kit, Miltenyi Biotec). Allogeneic stimulator cells were cultured at different numbers in triplicates with 2×105 T cells in 96-well round-bottomed culture plates for 48 hours. Proliferation of T cells was measured by uptake of 1 μCi 3H-Thymidine (Hartmann Analytik) pulsed for the last 16–18 hours of incubation.

**Macropinocytosis**

For the measurement of macropinocytosis immature BMDCs were washed and subsequently resuspended in PBS for incubation with 2 mg/ml FITC-dextran (Sigma Aldrich) at 37°C or at 4°C (negative control). After 2 and 4 hours, uptake was terminated by adding ice-cold PBS containing 2% FCS and 0.01% NaN3. Cells were washed a further four times and analyzed by flow cytometry. Surface binding values obtained when incubating cells at 4°C were subtracted from values measured at 37°C.

**Cytokine Secretion**

Immature 1×105 wildtype and cblb−/− BMDCs were stimulated in triplicates with 1 μg/ml TLR4 agonist (LPS; Sigma Aldrich), 20 μg/ml TLR3 agonist (Poly(I:C); Imgenex) or 100 nM TLR9 agonist (CpG-ODN; TIB Molbiol) on day seven of in vitro culture. After 24 hours, culture supernatants were collected and analyzed for IL-12p70, IL-10, IFN-γ, IL-1α, IL-6, TNF-α, KC, MIP-1α and MCP-1, according to the manufacturer’s manual by Bioplex (Bio-Plex Pro TM Mouse Cytokine Standard; 23-Plex, Group I, BioRad).

**In vivo BMDCs Migration**

Mycobacterium tuberculosis (TB; f.e = 0.125 mg; Voigt Global Distribution Inc.) in Freund’s incomplete adjuvants (FIA; Sigma Aldrich) was subcutaneously injected into the hock of 7–12 weeks old female C57BL/6 mice. Cblb−/− or wildtype BMDCs were pulsed with 10 μM SIINFEKL peptide (Proimmune) and stimulated with 100 ng/ml LPS for 4 hours. 2×105 SIINFEKL-loaded wildtype or cblb−/− BMDCs were subcutaneously injected into the contralateral flank of tumor-bearing mice, five days after tumor challenge. In all experimental groups, tumor growth was monitored three times per week by measuring tumor length and width with a caliper. Tumor volume was calculated as: (length×width2) ÷ π/6000. For survival analysis, mice with tumors above the length limit of 20 mm were sacrificed.

**Statistical Analysis**

The statistical analysis of the difference between mean values was performed using the paired Student’s t-test. Overall survival is expressed by the Kaplan-Meier method. P-values expressed as **p<0.005 or *p<0.05 were considered statistically significant. Numbers of carried out experiments are indicated in figure legends.

**Results**

Cbl-b is Highly Expressed in BMDCs and does not Affect BMDCs Differentiation in vitro

We first evaluated, whether Cbl-b is expressed in BMDCs. Therefore we analyzed protein expression of Cbl-b by Western blot using in vitro generated BMDCs. Cbl-b protein is readily detectable in highly pure (80–90% CD11c+/MHCII+) BMDCs but absent in cblb−/− BMDCs (Figure 1A). We next tested whether Cbl-b deficiency affects BMDC differentiation. However, no difference in BMDCs cell yields on day seven of in vitro GM-CSF mediated differentiation could be detected between wildtype and cblb−/− BMDCs (data not shown). This, however, does not exclude that cblb−/− BMDCs display a different phenotype.

**DEC-205 is Specifically Up-regulated in cblb−/− BMDCs**

We next investigated the surface marker expression of wildtype and cblb−/− BMDCs. Immature and LPS-stimulated mature BMDCs were analyzed for the expression of common DC surface markers by flow cytometry. Expression of BMDC markers, such as MHC class II, CD86, CD40, CD80, CD83, CD11b and macrophage mannose receptor/CD206 were not differentially regulated in cblb−/− versus wildtype BMDCs (Figure 1 B/C). However, we found a consistent increase of DEC-205 expression in cblb−/− BMDCs when compared to wildtype BMDCs (Figure 1 B/C).
Enhanced Proinflammatory Cytokine and Chemokine Secretion of cblb−/− BMDCs upon TLR Stimulation

Production of cytokines and chemokines upon activation is a key feature of DC function [37,38]. Therefore, we analyzed proinflammatory cytokine (IL-1β, IL-6, TNF-α, IL-12p70, IFN-γ) and chemokine (KC, MCP-1, MIP-1α) secretion of cblb−/− BMDCs activated by different TLR agonists. Upon stimulation of wildtype and cblb−/− BMDCs by the TLR4 agonist LPS, significantly higher amounts of TNF-α, IL-6 and the chemokine MIP-1α could be detected in the supernatant of stimulated cblb−/− BMDCs (Figure 2). Only a slight and statistically not significant increase in IL-1α could be detected in LPS-stimulated cblb−/− BMDCs, whereas secretion of IFN-γ, IL-10, MCP-1 and CXCL1 (KC) was not affected by cblb-deficiency. Upon stimulation with the TLR9 agonist CpG high amounts of the proinflammatory mediators IL-1α, TNF-α and the chemokine MCP-1 were detectable in cblb−/− versus wildtype BMDCs (Figure 2). In contrast, treating cells with the TLR3 agonist Poly(I:C) did not significantly alter their cytokine or chemokine secretion pattern (data not shown). Immature, non-stimulated BMDCs served as control and did not produce detectable amounts of cytokines (data not shown).

Increased Allogeneic T cell Priming Potential of cblb−/− BMDCs

Due to the increased production of cytokines, it is tempting to speculate that the T cell stimulatory capacity of cblb−/− BMDCs is modulated. Indeed, cblb−/− BMDCs were able to induce stronger allogeneic T cell priming capacity compared to wildtype BMDCs. To demonstrate this, T cells were prepared from spleens of BALB/c mice and co-cultured with LPS-matured wildtype or cblb−/− BMDCs. Increasing numbers of wildtype and cblb−/− BMDCs were incubated with a fixed number of allogeneic T cells for 48 hours. Our results in Figure 3A depict that BMDCs of cblb−/− mice are significantly more active MLR stimulators compared to wildtype BMDCs. Figure 3A shows that approximately 300 cblb−/− BMDCs could already trigger substantial T cell responses. The difference in induced T cell proliferation between wildtype and cblb−/− BMDCs was already significant at lower BMDC numbers (Figure 3A). The proliferation responses by T cells alone or BMDCs alone served as control and were always low and not distinguishable between the genotypes.
In vitro Antigen-specific T cell Proliferation not Altered by cblb\(^{-/-}\) BMDCs

We next analyzed in vitro activation properties of cblb\(^{-/-}\) BMDCs using T cell receptor transgenic mice, OVA-specific CD4\(^{+}\) (OT-II mice) and CD8\(^{+}\) (OT-I mice) T cells. Therefore SIINFEKL or ISQAVHAAHAEINEAGR peptide-pulsed BMDCs were cultured with OT-I or OT-II TCR transgenic T cells for two days. However, contrary to the MLR-data, cblb\(^{-/-}\) BMDCs are not able to induce more effective antigen specific CD8\(^{+}\) or CD4\(^{+}\) T cell responses when compared to wildtype BMDCs (Figure 3B/C).

In vivo Antigen-specific T cell Proliferation Unchanged by cblb\(^{-/-}\) BMDCs

To verify the in vitro antigen-specific T cell proliferation results in vivo, we next analyzed the T cell-responses by intravenous injection of CFSE-labeled TCR transgenic OT-I/CD8\(^{+}\) T cells, by subsequent injection of peptide or non-pulsed wildtype or
Three days thereafter, draining and non-draining lymph node, were evaluated for CD8\(^+\) T cell proliferation by CFSE dilution (Figure 3D). Most of the OT-I\(^+\) T cells in the draining lymph node entered cell cycle and underwent five cell divisions after injection of peptide-pulsed BMDCs, no matter if wildtype or cblb\(^{-/-}\) BMDCs were applied. The unloaded BMDCs group elicited no proliferation and served as control group (Figure 3D). Equal to the in vitro results, no increased
antigen-specific T cell proliferation could be induced by cblb−/− BMDCs in vivo, concluding that Cbl-b plays no relevant role in antigen-specific T cell priming in the OVA system tested here.

Cross-presentation Capacity of cblb−/− BMDCs is not Affected
In the next set of experiments we used the protein antigen OVA to test the cross-presentation capacity of cblb−/− BMDCs. Therefore wildtype and cblb−/− BMDCs were incubated with soluble OVA-protein instead of peptides and in vitro cultured with OT-I CD8+ and OT-II CD4+ TCR transgenic T cells for two days. Cblb−/− BMDCs induced proliferation rates comparable to wildtype BMDCs (Figure 3E/F). These results indicate that the induction of T cell responses by cross-presentation of OVA-peptides to the MHC-I receptor and the presentation of OVA-peptides to the MHC-II receptor is not affected by cblb-deficiency.

Unaltered Macropinocytosis in cblb−/− BMDCs versus Wildtype BMDCs
We next analyzed the mechanisms of antigen uptake by BMDCs via macropinocytosis. Therefore immature BMDCs generated from either wildtype or cblb−/− animals were incubated with FITC Dextran and uptake was analyzed by flow cytometry (Figure 4A/B). Interestingly, immature BMDCs generated from cblb−/− mice showed comparable levels of FITC-dextran uptake when compared to wildtype BMDCs (Figure 4A/B). As we could detect upregulation of cytokine secretion by cblb−/− BMDCs (Figure 2), we additionally tested, whether these results could influence the ability of cblb−/− BMDCs to migrate from peripheral tissues to the T cell areas of draining lymphoid organs.

Unaltered cblb−/− BMDCs Migration in vivo
Using an in vivo migration assay we investigated whether the absence of Cbl-b could influence the migration potential of BMDCs. Therefore, we induced peripheral inflammation by the injection of TB-FIA into the hock of mice and subsequently measured migration of differentially labeled wildtype and cblb−/− BMDCs to the draining lymph node. CFSE labeled wildtype and TAMRA labeled cblb−/− BMDCs were injected into the hock two days after induction of inflammation. 24 hours thereafter, migration of the dye-labeled BMDCs in the draining lymph node (Figure 5A) and non-draining lymph node as control was measured by flow cytometry. In all experiments, dye-labeled BMDCs were clearly detectable. BMDCs migrate best into the local draining (popliteal) lymph node and were not detectable in the inguinal lymph node. In solvent injected control mice the transferred BMDCs failed to migrate into the draining lymph node regardless of genotypy. This migration assay revealed that both, cblb−/− and wildtype BMDCs were able to migrate properly to local draining lymph nodes (Figure 5A).

Cblb−/− and Wildtype BMDCs have Equal Potential as Tumor Vaccine
To assess whether cblb-deficiency in BMDCs would increase their ability to infiltrate and reject tumors, fully immune-competent C57BL/6 wildtype mice were subcutaneously injected with B16-OVA melanoma cells and vaccinated with semi-matured SIINFEKL-loaded BMDCs from wildtype and cblb−/− donors on day five. Control groups received PBS solvent only. While at day 24 all mice in the untreated group had to be sacrificed due to large tumor sizes, treatment with SIINFEKL-loaded wildtype or cblb−/− BMDCs substantially delayed tumor outgrowth (Figure 5B). However, tumor growth suppression and survival was comparable in mice receiving cblb−/− BMDCs compared to wildtype BMDCs (Figure 5B/C).

Discussion
The here presented study is based on a recently published article of Shin-Heng Chiou et al., who postulated that the E3 ligase c-Cbl plays a critical role in DC biology [9]. They identified a proinflammatory phenotype of cblb−/− versus wildtype BMDCs, which is accompanied with an increased potency as DC-based vaccine against established tumors. So far, it was entirely unknown whether Cbl-b is expressed and – if so – modulates DC biology. Therefore, we have systematically compared wildtype with cblb−/− BMDCs and conclude from our data that Cbl-b has only limited impact on the functional properties of murine BMDCs.

Our results show that Cbl-b protein is highly expressed in murine BMDCs. Absence of Cbl-b does not inhibit BMDC differentiation in vitro, as we were not able to detect altered differentiation of BMDCs in a seven day culture when compared to wildtype BMDCs. When we focused on the phenotype of cblb−/− BMDCs however, we were able to detect a significant and consistent increase of the endocytotic receptor DEC-205 in cblb−/− BMDCs, while other DC markers, such as CD206, CD83 and CD11b or the DC activation markers MHC class II, CD40, CD80 and CD86 were not differentially expressed.

A hallmark of DC function is the paracrine regulation of immune cells by production of cytokines and chemokines such as IL-1α, IL-1β, TNF-α, IL-6 MIP-1α, and β [39–41]. One mechanism is pathogen recognition by TLRs, which provokes rapid activation of the immune system by inducing expression of proinflammatory cytokines. It has recently been demonstrated that E3 ubiquitin ligase Cbl-b degrades MyD88, a critical component of TLR-signaling [10–13]. Whereas the stimulation of TLR4 and TLR9 mainly facilitates the activation of the MyD88 dependent pathway which leads to the production of inflammatory cytokines, TLR3 signaling seems to transduce its signals mainly through the MyD88-independent pathway [42,43]. According to this concept, we here show that there is a general trend towards higher cytokine production upon stimulation of DCs with LPS or CpG, reaching statistical significance for IL-1α, TNF-α for both TLR-agonists as well as IL-6 and MIP-1α for LPS and MCP-1 for CpG. This observation is in line with the paper of Shin-Heng Chiou et al., which showed increased proinflammatory cytokine secretion of cblb−/− BMDCs after TLR stimulation. However, no alterations in TLR3 mediated cytokine expression could be observed between wt and cblb−/− BMDCs, which further confirms that Cbl-b degrades MyD88 and the subsequent suppression of MyD88 dependent inflammatory responses. Thus Cbl-b might function as a negative regulator of TLR triggered inflammatory responses by directly inhibiting and degrading MyD88 [10].

Interestingly, cblb−/− BMDCs are more effective inducers of an allogeneic T cell proliferation in MLR cultures, whereas their potential to induce antigen-specific T cell responses against both, MHC class I- or class II-restricted OVA-peptides, was not affected. Whereas the increased levels of proinflammatory cytokines and chemokines could be linked to an increased allogeneic T cell proliferation, the peptide-induced T cell proliferation seems to be less sensitive of the modulated cytokine milieu. This could be due to the fact that OT-I and OT-II T cells may already be committed to activation or proliferation by just minor stimuli, where very low concentrations of Ag are sufficient to induce strong proliferation. Therefore the increase in cytokine production by cblb−/− BMDCs may not be sufficient to influence
OT-I and OT-II T cells in their peptide-induced proliferation response. Activation of DCs also stimulates T cells to produce a variety of cytokines, and recent studies suggest that some of these cytokines may provide, next to co-stimulatory ligands and the Ag presented by DCs, an essential third signal that is required to fully activate T cells and avoid tolerance induction. Recent reports further showed that stimulation of CD8$^+$ T cells with a high level of Ag in the presence of co-stimulation can lead to strong \textit{in vitro} proliferation but the cells fail to develop effector function unless signal 3 in the form of the cytokine IL-12 is also provided. Thus, cblb$^{2/2}$ BMDCs are not different from wt BMDCs with regard to the induction of Ag-specific clonal expansion but may modify other functions, such as induction of tolerance or effector functions [44,45], which we have not specifically addressed in this report.

To explore whether these \textit{in vitro} observations also hold true \textit{in vivo}, we next tested the T cell proliferation capacity of adoptively transferred TCR transgenic CD8$^+$/OT-I T cells, in response to SIINFEKL peptide loaded wildtype versus cblb$^{2/2}$ BMDCs. Consistent with the results from our \textit{in vitro} studies, we were not able to detect a difference of the \textit{in vivo} T cell proliferation induced by wt or cblb$^{2/2}$ BMDCs.

As cross-presentation provides the immune system with an important mechanism for generating immunity to viruses and tolerance to self, we further tested if cblb$^{2/2}$ BMDCs could incorporate and process proteins \textit{via} the endocytotic machinery [46]. Using this approach, we were able to demonstrate that the processing of proteins to MHC class I and class II seems not to be impaired in cblb$^{2/2}$ BMDCs. This result correlates with our surface marker characterisation of cblb$^{2/2}$ BMDCs, as no alteration in the expression of the CD206 receptor could be observed and it has been described that the mannose receptor is an uptake receptor for OVA protein [47].

Capture of Antigens by surface receptors such as Fc-Receptors, Mannose Receptors [e.g. CD206] or DEC-205 receptors allows efficient delivery of the antigen to the processing compartment \textit{via} receptor-mediated endocytosis [48–50]. Antigens that fail to bind to cell surface receptors can still be taken up by fluid phase pinocytosis and presented by antigen presenting cells (APC) but with much lower efficiency [51]. Of note, macropinocytosis was not statistically different between cblb$^{2/2}$ and wt BMDCs. However, it is also conceivable that DEC-205 expression in DCs might be relevant for steady state function of DCs, as DEC-205 for example has been shown to be associated with regulatory T cell induction thereby regulating peripheral tolerance [52–55].

The capacity of DCs to migrate into T cell areas of lymph nodes is a key event in initiating immunity, and it may represent a critical step for the induction of an anti-tumor immune response. DCs are also known to produce different immune stimulatory cytokines and chemokines thereby regulating the traffic of Th1 and Th2 cells into inflamed tissue. Thus we further questioned if Cbl-b could play a role in the migration potential of DCs into inflamed tissue [38]. Here we could clearly show that cblb$^{2/2}$ BMDCs are as potent in migration to local lymph nodes after subcutaneous injection as wildtype BMDCs are. The data are in agreement with the observation that the critical lymph node-homing receptor for DC-migration from the periphery into the lymph node CCR7 was not affected by cblb-deficiency (data not shown) [56,57].

Figure 4. Macropinocytosis is not altered by cblb$^{-/-}$ deficiency. (A) Macropinocytosis was quantified by incubating immature day seven BMDCs with 2 mg/ml FITC-dextran at 37°C or at 4°C (negative control). After 2 and 4 hours, uptake was stopped and analyzed by FACS. Data represent mean value $\pm$ SEM; n=4. (B) Representative dot plot of 4 independent experiments is shown.

doi:10.1371/journal.pone.0065178.g004
We next explored whether Cbl-b deficiency might improve therapeutic potential of a BMDC vaccine applied in the B16-OVA model. However the vaccination of tumor-bearing animals with SIINFEKL-pulsed cblb-/- BMDCs showed no difference, neither in tumor regression nor in survival rates when compared to wildtype BMDC application. In contrast to the data from c-Cbl deleted mice we conclude from these experiments that despite higher DEC-205 expression and an increased expression of proinflammatory cytokines and chemokines upon TLR-stimulation, the concept of Cbl-b targeting alone in DCs is not suitable to increase the efficacy of DC vaccines in vivo.

Acknowledgments

We thank Nikolaus Romani (Department of Dermatology and Venereology, Medical University Innsbruck) for helpful discussions throughout this project and the perfect technical assistance of Franziska Spock is acknowledged.

Author Contributions

Conceived and designed the experiments: SW CT. Performed the experiments: SW CLN. Analyzed the data: SW CT PS DW. Contributed reagents/materials/analysis tools: CT GG JP GB. Wrote the paper: SW DW.

References

1. Steinman RM (2012) Decisions about dendritic cells: past, present, and future. Annual Review of Immunology 30: 1–22.
2. Den Brok MHJGM, Nierkens S, Figdor CG, Ruers TJM, Adema GJ (2005) Dendritic cells: tools and targets for antitumor vaccination. Expert Review of Vaccines 4: 699–710.
3. Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, et al. (1998) Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. The Prostate 36: 39–44.
4. Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM (2009) Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunology, Immunotherapy 58: 1–14.
5. Delamarre L, Mollman I (2011) Harnessing dendritic cells for immunotherapy. Seminars in Immunology 23: 2–11.
6. Schulze G (2010) Dendritic cells in cancer immunotherapy. European Journal of Immunology 40: 2123–2130.
7. Nau MM, Lipkowitz S (2003) Comparative genomic organization of the cbl genes. Gene 308: 103–113.
8. Wallner S, Gruber T, Baier G, Wolf D (2012) Targeting Cbl-b to enhance lymphocyte effector function. Developmental and Clinical Immunology 2012: 1–5.
9. Chou S-H, Shahi P, Wagner RT, Hu H, Lapteva N, et al. (2011) The E3 ligase c-Cbl regulates dendritic cell activation. EMBO reports: 1–9.
10. Han C, Jin J, Xu S, Liu H, Li N, et al. (2010) Integrin CD11b negatively regulates TLR-triggered inflammatory responses by activating Syk and promoting degradation of MyD88 and TRIF via Cbl-b. Nature Immunology 11: 734–742.
11. Kaisho T, Akira S (2002) Toll-like receptors as adjuvant receptors. Biochimica et Biophysica Acta 1509: 1–15.
12. Takeda K, Kaisho T, Akira S (2003) Toll-like receptors. Annual Review of Immunology 21: 335–376.
13. Takeda K (2005) Toll-like Receptors and their Adaptors in Inmate Immunity. Science: 3–11.
14. Nurieva R, Thomas S, Nguyen T, Martin-Orozco N, Wang Y, et al. (2006) T-cell tolerance or function is determined by combinatorial costimulatory signals. The EMBO Journal 25: 2623–2633.

Figure 5. Migration capacity and therapeutic potential as tumor vaccine of cblb-/- BMDCs. (A) 0.125 mg of TB in FIA was injected in a total volume of 50 µl per hock into wildtype recipients. On day two CFSE labeled wildtype and TAMRA labeled cblb-/- BMDCs were injected in the hock in wildtype control recipients and TB injected recipients. 24 hours thereafter migration of the BMDCs in the draining lymph node (not shown) was measured by flow cytometry. Data represent mean value ± SEM, n = 4 mice per group, two independent experiments. (B) 1 x 10^7 B16-OVA cells were injected subcutaneously into the left flank of wildtype recipients. Tumor-bearing mice were subcutaneously vaccinated into the opposite right flank on day five with 2 x 10^6 10 µM SIINFEKL primed semi-mature wildtype versus cblb-/- BMDCs. Tumor growth was monitored thereafter every two/three days. Control animals received PBS. All data points represent tumor volume (mean value ± SEM, n = 4 mice), representative of two independent experiments is shown. (C) Survival of the same animals described in (B) was monitored. doi:10.1371/journal.pone.0065178.g005
15. Karwacz K, Broigne C, MacDonald D, Arce F, Bennett CL, et al. (2011) PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Molecular Medicine 3: 581–592.

16. Braham JR, Tykkö S, Chow LQM, Hwu WJ, Topalian SL, et al. (2013) Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. New England Journal of Medicine 366: 2455–2465.

17. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. (2012) Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. New England Journal of Medicine 366: 2443–2454.

18. Heismeyer V, Macian F, Im S-H, Varma R, Feske S, et al. (2004) Calcineurin imposes T cell unresponsiveness through targeted proteinolysis of signaling proteins. Nature Immunology 5: 253–263.

19. Jean M-S, Artifial A, Vempraasad K, Krawczyk C, Sarao R, et al. (2004) Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity 21: 167–177.

20. Kojo S, Elly C, Harada Y, Langlois WY, Kroening M, et al. (2000) Mechanisms of NK cell anergy induction involving Cbl-b-promoted mono-ubiquitination of CARMA1. Proceedings of the National Academy of Sciences of the United States of America 106: 17047–17051.

21. Chiang VJ, Kole HK, Brown K, Narazuma M, Fujikura S, et al. (2000) Cbl-b regulates the CD80 dependence of T-cell activation. Nature 403: 216–220.

22. Paolini M, Thien CBF, Gruber T, Hinterleiner R, Baier G, et al. (2011) Essential role of E3 ubiquitin ligase activity in Cbl-b-regulated T cell functions. Journal of Immunology 186: 2136–2147.

23. Loeser S, Loer K, Bijker MS, Ranagachi M, van der Burg SH, et al. (2007) Spontaneous tumor rejection by cbl-b-deficient CD8 T cells. The Journal of Experimental Medicine 204: 879–891.

24. Bachmair K, Krawczyk C, Keziriantad I, Kong V-Y, Sasaki T, et al. (2000) Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 403: 211–216.

25. Krawczyk CM, Jones RG, Atfield A, Bachmaier K, Arya S, et al. (2005) Differential control of CD28-regulated in vivo immunity by the E3 ligase Cbl-b. The Journal of Immunology 174: 1472–1478.

26. Wohlfert EA, Callahan MK, Clark RB (2004) Resistance to CD4 T cell-mediated delayed-type hypersensitivity. The Journal of Immunology 172: 1659–1666.

27. Wohlfert EA, Gorelik L, Mittler R, Flavell RA, Clark RB (2006) Cutting Edge: Deficiency in the E3 Ubiquitin Ligase Cbl-b Results in a Multifunctional Defect in T Cell TGFBbeta Sensitivity in Vivo and In Vivo. Journal of Immunology 176: 1316–1320.

28. Lutz-Nicoladoni C, Wallner S, Stoitzner P, Pircher M, Gruber T, et al. (2011) Reinforcement of cancer immunotherapy by adoptive transfer of cbl-b-deficient CD8 T cells combined with a DC vaccine. Immunology and Cell Biology 2011: 389–400.

29. Parev E, Netl I, Horne WC, Baron R (2009) c-Cbl and Cbl-b Act Redundantly to Protect Osteoclasts from Apoptosis and to Displace HADAC6 from beta-Tubulin, Stabilizing Microtubules and Podosomes. Molecular Biology of the Cell 20: 4021–4030.

30. Huang F, Gu H (2008) Negative regulation of lymphocyte development and function by the Cbl family of proteins. Immunological Reviews 224: 229–238.

31. Lutz MB, Kukutsch N, Ogilvie ALJ, Redline S, Koch F, et al. (1999) An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. Journal of Immunological Methods 223: 77–92.

32. McDellan AD (2002) Anatomic location and T-cell stimulatory functions of anatomic location and T-cell stimulatory functions of mouse dendritic cell subsets defined by CD4 and CD8 expression. Blood 99: 3084–3093.

33. Lyons AB (2001) Cross-presentation in viral immunity and self-tolerance. Nature Immunology 1: 135–145.

34.幕墙 T, 崔克 C (2004) Toll-like receptors and innate immunity. Nature Reviews Immunology 4: 576–588.

35.幕墙 T, 崔克 C (2004) Toll-like receptor signalling. Nature Reviews Immunology 4: 499–511.

36.幕墙 T, 崔克 C (2004) Toll-like receptor signalling. Nature Reviews Immunology 4: 499–511.

37.幕墙 T, 崔克 C (2004) Toll-like receptor signalling. Nature Reviews Immunology 4: 499–511.